JP2024503898A5 - - Google Patents

Info

Publication number
JP2024503898A5
JP2024503898A5 JP2023544070A JP2023544070A JP2024503898A5 JP 2024503898 A5 JP2024503898 A5 JP 2024503898A5 JP 2023544070 A JP2023544070 A JP 2023544070A JP 2023544070 A JP2023544070 A JP 2023544070A JP 2024503898 A5 JP2024503898 A5 JP 2024503898A5
Authority
JP
Japan
Prior art keywords
formula
independently
sulfur
oxygen
heteroatoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023544070A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503898A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/070308 external-priority patent/WO2022159976A1/en
Publication of JP2024503898A publication Critical patent/JP2024503898A/ja
Publication of JP2024503898A5 publication Critical patent/JP2024503898A5/ja
Pending legal-status Critical Current

Links

JP2023544070A 2021-01-22 2022-01-24 ラパマイシン類似体及びその使用 Pending JP2024503898A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163140523P 2021-01-22 2021-01-22
US63/140,523 2021-01-22
US202163202524P 2021-06-15 2021-06-15
US63/202,524 2021-06-15
PCT/US2022/070308 WO2022159976A1 (en) 2021-01-22 2022-01-24 Rapamycin analogs and uses thereof

Publications (2)

Publication Number Publication Date
JP2024503898A JP2024503898A (ja) 2024-01-29
JP2024503898A5 true JP2024503898A5 (cg-RX-API-DMAC7.html) 2025-02-03

Family

ID=82549982

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023544070A Pending JP2024503898A (ja) 2021-01-22 2022-01-24 ラパマイシン類似体及びその使用

Country Status (9)

Country Link
US (1) US20220267352A1 (cg-RX-API-DMAC7.html)
EP (1) EP4281463A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024503898A (cg-RX-API-DMAC7.html)
KR (1) KR20230136625A (cg-RX-API-DMAC7.html)
AU (1) AU2022209863A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023014287A2 (cg-RX-API-DMAC7.html)
CA (1) CA3209086A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023008634A (cg-RX-API-DMAC7.html)
WO (1) WO2022159976A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3127448C (en) 2019-01-22 2024-06-04 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
CN115776907B (zh) 2020-03-27 2025-02-25 艾奥维安制药公司 Mtorc1调节剂及其用途
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA935110B (en) * 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
EP2051984A1 (en) * 2006-07-25 2009-04-29 Abbott Laboratories Crystalline forms of rapamycin analogs
US20130035336A1 (en) * 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
JP5985474B2 (ja) * 2010-08-04 2016-09-06 メリル ライフ サイエンシズ ピーブィティ.エルティディ 抗増殖特性を有する新規42−o−(ヘテロアルコキシアルキル)ラパマイシン化合物の調製プロセス
US10683308B2 (en) * 2015-09-11 2020-06-16 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
US10980784B2 (en) * 2018-06-15 2021-04-20 Navitor Pharmaceuticals, Inc. Rapamycin analogs and uses thereof
WO2020076738A2 (en) * 2018-10-12 2020-04-16 Bellicum Pharmaceuticals, Inc Protein-binding compounds
CA3127448C (en) * 2019-01-22 2024-06-04 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
EP4069223A4 (en) * 2019-12-05 2023-12-20 Janssen Pharmaceutica NV RAPAMYCIN ANALOGS AND THEIR USES

Similar Documents

Publication Publication Date Title
JP2023506410A5 (cg-RX-API-DMAC7.html)
JP2022505835A5 (cg-RX-API-DMAC7.html)
JP6134046B1 (ja) 医療で使用されるインドール誘導体
WO2018013597A4 (en) 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
JP2019520417A5 (cg-RX-API-DMAC7.html)
JP2021502387A5 (cg-RX-API-DMAC7.html)
JP2022548095A5 (cg-RX-API-DMAC7.html)
JP2018505898A5 (cg-RX-API-DMAC7.html)
JP2018529650A5 (cg-RX-API-DMAC7.html)
JP2022545359A5 (cg-RX-API-DMAC7.html)
JP2009513703A5 (cg-RX-API-DMAC7.html)
CN115605479A (zh) 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用
JP2011515482A5 (cg-RX-API-DMAC7.html)
JP2022511477A5 (cg-RX-API-DMAC7.html)
JP2017524005A5 (cg-RX-API-DMAC7.html)
JP2010510237A5 (cg-RX-API-DMAC7.html)
JP2018535963A5 (cg-RX-API-DMAC7.html)
JP2020502047A5 (cg-RX-API-DMAC7.html)
JP7778745B2 (ja) Rho関連コイルドコイル含有プロテインキナーゼの阻害剤
JP2011509309A5 (cg-RX-API-DMAC7.html)
JP2018515623A5 (cg-RX-API-DMAC7.html)
JP2010533699A5 (cg-RX-API-DMAC7.html)
RU2012141706A (ru) Производные оксадиазола и их применение в качестве потенцирующих средств в отношении метаботропных глутаматных рецепторов-842
JP2021521178A5 (cg-RX-API-DMAC7.html)
JP2020533352A5 (cg-RX-API-DMAC7.html)